文献・資料をご希望の際は、資料請求ページの備考欄に見出し番号（下記リストの赤色の数字）を入力の上、ご連絡ください。

資料請求はこちら ▶

慢性腎臓病（CKD）関連文献 一覧 【新着順】

• 203Clinical utility of tubular markers in kidney disease: a narrative review. J Lab Precis Med.2022
  doi: 10.21037/jlpm-22-24JLPM
• 200Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis. Front Med (Lausanne).2022
  doi: 10.3389/fmed.2022.914587PubMed
• 199Effects of dietary phosphorus concentration and phosphate salt form on renal tubule function in unilateral nephrectomized rats . Nutr Health.2022
  doi: 10.1177/02601060221122223PubMed
• 196Early, Noninvasive Clinical Indicators of Kidney Prognosis in Primary Nephrotic Syndrome: A Retrospective Exploratory Study . Int J Nephrol.2022
  doi: 10.1155/2022/2718810 PubMed
• 190Biomarkers for the early prediction of contrast-induced nephropathy after percutaneous coronary intervention in adults: A systematic review and meta-analysis. Angiology.2022
  doi: 10.1177/00033197211039921.PubMed
• 189 Usefulness of urinary tubule injury markers for predicting progression of renal dysfunction in patients with type 2 diabetes and albuminuria: The Fukuoka Diabetes Registry. Diabetes Res Clin Pract.2022
  doi: 10.1016/j.diabres.2022.109840.PubMed
• 182 Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis. Tohoku J Exp Med.2021
  doi: 10.1620/tjem.255.291. PubMed
• 179 Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial. J Diabetes Res.2021
  doi: 10.1155/2021/7382620. PubMed
• 178 Exercise Ameliorates Diabetic Kidney Disease in Type 2 Diabetic Fatty Rats. Antioxidants (Basel).2021
  doi: 10.3390/antiox10111754. PubMed
• 176 Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs. J Vet Med Sci.2021
  doi: 10.1292/jvms.20-0698. PubMed
• 174 Amniotic Fluid L-Type Fatty Acid-Binding Protein in Predicting Fetal Condition. Tohoku J Exp Med.2021
  doi: 10.1620/tjem.254.267. PubMed
• 168 Renal hemodynamics across the adult lifespan: Relevance of flow pulsatility to chronic kidney disease. Exp Gerontol.2021
  doi: 10.1016/j.exger.2021.111459. PubMed
• 166 Relationship of urinary liver-type fatty acid-binding protein with cardiovascular risk factors in the Japanese population without chronic kidney disease: Sasayama study. BMC Nephrol.2021
  doi: 10.1186/s12882-021-02398-8. PubMed
• 165 Preliminary study of urinary excretion of liver-type fatty acid-binding protein in a cat model of chronic kidney disease. Can J Vet Res.2021
  PubMed
• 164 Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients. J Med Biochem.2020
  doi: 10.2478/jomb-2019-0037. PubMed
• 163 Liver-type fatty acid-binding protein and neutrophil gelatinase-associated lipocalin in cats with chronic kidney disease and hyperthyroidism. J Vet Intern Med.2021
  doi: 10.1111/jvim.16074. PubMed
• 162 Predictive value of novel biomarkers for chronic kidney disease among workers occupationally exposed to silica. Toxicol Ind Health.2021
  doi: 10.1177/0748233721990304. PubMed
• 161Urinary liver-type fatty acid-binding protein is a predictor of mortality in individuals with type 2 diabetes. Diabet Med.2021
  doi: 10.1111/dme.14527. PubMed
• 160 Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.Clin Exp Nephrol.2021
  doi: 10.1007/s10157-020-02007-2. PubMed
• 158 Urinary Liver-type Fatty Acid-Binding Protein Predicts Residual Renal Function Decline in Peritoneal Dialysis Patients. Med Sci Monit.2020
  doi: 10.12659/MSM.928236 PubMed
• 157 Novel Urinary Biomarkers and Chronic Kidney Disease After Coronary Angiography: A Prospective Case-Controlled Study. Open Access Maced J Med Sci.2020
  doi: 10.3889/oamjms.2020.4857 OAMJMS
• 154 Longitudinal kidney injury biomarker trajectories in children with obstructive uropathy. Pediatr Nephrol.2020
  doi: 10.1007/s00467-020-04602-7 PubMed
• 152 Increased Urinary Liver-Type Fatty Acid-Binding Protein Level Predicts Major Adverse Cardiovascular Events in Patients with Hypertension. Am J Hypertens.2020PubMed
• 151 Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease. J Vet Intern Med. 2020PubMed
• 149 Relationship between Urinary Liver-Type Fatty Acid-Binding Protein (L-FABP) and Sarcopenia in Spontaneously Diabetic Torii Fatty Rats. J Diabetes Res.2020Hindawi
• 148 Effects of exercise on residual renal function in patients undergoing peritoneal dialysis: a post-hoc analysis of a randomized controlled trial. Ther Apher Dial.2020PubMed
• 146Evaluation of liver-type fatty acid binding protein (L-FABP) and interleukin 6 in children with renal cysts.Adv Clin Exp Med.2019PubMed
• 145The influence of renal function by ibuprofen treatment for patent ductus arteriosus in extremely low-birth-weight infants.Pediatr Int.2019PubMed
• 144The Possibility of Urinary Liver-Type Fatty Acid-Binding Protein as a Biomarker of Renal Hypoxia in Spontaneously Diabetic Torii Fatty Rats.Kidney Blood Press Res.2019PubMed
• 140Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary β2 microglobulin levels: a retrospective observational study.J Pharm Health Care Sci.2019PubMed
• 139Renoprotective effects of voluntary running exercise training on aldosterone-induced renal injury in human L-FABP chromosomal transgenic mice.Hypertens Res.2019PubMed
• 138Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study.Diabetol Int. 2018PubMed
• 137Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease.Kidney Blood Press Res. 2018PubMed
• 134Urinary liver-type fatty acid-binding protein levels as a potential risk factor for renal dysfunction in male HIV-infected Japanese patients receiving antiretroviral therapy: a pilot study.Int J STD AIDS. 2018PubMed
• 130Urinary L-FABP level in children with nephrotic syndrome and tubular dysfunction.Pediatr Int.2018PubMed
• 129Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucoselowering-independent manner.BMJ Open Diabetes Res Care.2017PubMed
• 127Prediction of contrast induced acute kidney injury using novel biomarkers following contrast coronary angiography.QJM.2018PubMed
• 126Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury.Hypertens Res.2017PubMed
• 125Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression.Eur J Pharmacol.2017PubMed
• 124Urinary liver-type fatty acid-binding protein is associated with subendocardial viability ratio in middle- and older-aged adults.Clin Exp Hypertens.2017PubMed
• 121Urine liver fatty acid binding protein and chronic kidney disease progression.Scand J Clin Lab Invest.2017PubMed
• 120Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes.Diabetologia.2017 PubMed
• 119Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes.JClin Med Res.2017PubMed
• 116Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion.Nephrology.2017PubMed
• 113The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients.Clin Exp Nephrol.2016PubMed
• 111Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.FASEB J.2016PubMed
• 107Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.Cardiovasc Diabetol.15(1): 76, 2016.PubMed
• 106Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury.Am J Physiol Renal Physiol.310(11):F1366-1376, 2016.PubMed
• 104Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease.Clin Chem Lab Med.2016.PubMed
• 102Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD.Clin Exp Nephrol.20(2): 195-203, 2016.PubMed
• 99Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes.Pediatr Nephrol.31(4):623-631, 2016.PubMed
• 96Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats.Physiol Rep.3(12), 2015.PubMed
• 95Urinary liver-type fatty acid-binding protein change in gestational diabetes mellitus.Diabetes Res Clin Pract.109(3): e36-e38, 2015.PubMed
• 94Urinary Biomarkers and Risk of ESRD in the Atherosclerosis Risk in Communities Study.Clin J Am Soc Nephrol.10(11):1956-1963, 2015.PubMed
• 91Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.Scand J Clin Lab Invest.75(5): 421-427, 2015.PubMed
• 89Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment? Nephrology.10(4):e0122212, 2015.PubMed
• 88Distinct roles of urinary liver-type Fatty Acid-binding protein in non-diabetic patients with anemia.PLoS One.10(5): e0126990, 2015.PubMed
• 87Circulating TNF Receptors 1 and 2 Are Associated with the Severity of Renal Interstitial Fibrosis in IgA Nephropathy.PLoS One.10(4): e0122212, 2015.PubMed
• 85Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.Clin Exp Nephrol.19(6): 1044-1053, 2015.PubMed
• 84Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus.Diabetologia.58(1): 188-198, 2015.PubMed
• 81LDL-apheresis contributes to survival extension and renal function maintenance of severe diabetic nephropathy patients: a retrospective analysis.Diabetes Res Clin Pract.106(2): 241-246, 2014.PubMed
• 80NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction.Clin Chem Lab Med.52(4): 537-546, 2014.PubMed
• 74Urinary biomarkers of kidney injury are associated with all-cause mortality in the Women’s Interagency HIV Study (WIHS).HIV Med.15(5): 291-300, 2014.PubMed
• 72Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2.Heart Vessels.30(3): 362-368, 2014.PubMed
• 71Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.Diabetes Metab Res Rev.30(8): 736-741, 2014.PubMed
• 70Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.AIDS Res Hum Retroviruses.30(4): 363-369, 2014.PubMed
• 63Moderate-intensity single exercise session does not induce renal damage.J Clin Lab Anal.27(3): 177-180, 2013.PubMed
• 62A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.Am J Physiol Renal Physiol.305(12): F1796-1803, 2013.PubMed
• 60Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy.Diabetes Care.36(5): 1248-1253, 2013.PubMed
• 58Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.Diabet Med.29(8): e184-190, 2012.PubMed
• 56Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.Hypertens Res.35(11): 1058-1062, 2012.PubMed
• 51Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET).Internal Medicine.50(12): 1273-1278, 2011.PubMed
• 50Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.Hypertens Res .34: 935-941, 2011.PubMed
• 48Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy.Nephrol Dial Transplant.26(7): 2127-2137, 2011.PubMed
• 45Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.Nephrol Dial Transplant.26(11): 3465-3473, 2011.PubMed
• 44Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients.Diabetes Care.34(3): 691-696, 2011.PubMed
• 41Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.Eur J Clin Invest.40(2): 95-102, 2010.PubMed
• 40Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients.Diabetes Care.33(6): 1320-1324, 2010.PubMed
• 39Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.Am J Med Sci.339(2): 157-163, 2010.PubMed
• 38Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.Kidney Blood Press Res.33(3): 213-220, 2010.PubMed
• 37Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.Eur J Clin Invest.40(9): 790-796, 2010.PubMed
• 34Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.Nephron Clin Pract.112(3): c148-156, 2009.PubMed
• 33Tubular and glomerular injury in diabetes and the impact of ACE inhibition.Diabetes Care.32(9): 1684-1688, 2009.PubMed
• 30Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.Metabolism.58(8): 1185-1190, 2009.PubMed
• 29Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice.Nephrol Dial Transplant.24(3): 788-800, 2009.PubMed
• 25Renoprotective effect of telmisartan in patients with chronic kidney disease.Clin Exp Hypertens.30(7): 662-672, 2008.PubMed
• 24Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.Clin Nephrol.70(5): 385-392, 2008.PubMed
• 21Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.Diabetologia.50(2): 490-492, 2007.PubMed
• 20Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.Am J Med Sci.333(6): 321-326, 2007.PubMed
• 19Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.Am J Hypertens.20(11): 1195-1201, 2007.PubMed
• 16Cigarette smoking affects urinary liver-type fatty acid-binding protein concentration in patients with early diabetic nephropathy.Diabetes Care.29(7): 1717, 2006.PubMed
• 15Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.Clin Nephrol.65(1): 1-6, 2006.PubMed
• 14Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.Diabetes Metab Res Rev.22(5): 385-389, 2006.PubMed
• 13Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia.Am J Nephrol.26(3): 276-280, 2006.PubMed
• 12Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.Am J Nephrol.26(1): 82-86, 2006.PubMed
• 11Liver-type fatty acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction.Am J Pathol.169(4): 1107-1117, 2006.PubMed
• 10Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.Mol Cell Biochem.284(1-2): 175-182, 2006.PubMed
• 8Clinical Significance of Urinary Liver-Type Fatty acid-binding Protein in Patients With Diabetic Nephropathy.Diabetes Care.28(18): 2038-2039, 2005.PubMed
• 7Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.TAm J Med Sci.330(4): 161-165, 2005.PubMed
• 6Effect of Pitavastatin on Urinary Liver-Type Fatty acid-binding Protein Levels in Patients With Early Diabetic Nephropathy.Diabetes Care.28(11): 2728-2732, 2005.PubMed
• 5Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy.Am J Nephrol.25(5): 447-450, 2005.PubMed
• 4Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial.J Lab Clin Med.145(3): 125-133, 2005.PubMed
• 3Urinary excretion of liver fatty acid-binding protein in health-check participants.Clin Exp Nephrol.9(1): 34-39, 2005.PubMed
• 2Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.Am J Pathol.165(4): 1243-1255, 2004.PubMed
• 1Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease.J Lab Clin Med.143(1): 23-30, 2004.PubMed

文献・資料をご希望の際は、資料請求ページの備考欄に見出し番号（下記リストの最初の数字）を入力の上、ご連絡ください。

資料請求はこちら ▶

文献カテゴリー

慢性腎臓病（CKD）　急性腎障害（AKI）　薬剤性腎障害（Toxicology）
薬理学（Pharmacology）　運動（Exercise）　新型コロナウイルス感染症（COVID-19）　日本語総説　ガイドラインなど